



Justification for removing a substance from CoRAP prior to evaluation

Substance Name (public name): Oxirane, mono[(C12-14-alkyloxy)methyl] derivs.

EC Number: 271-846-8

CAS Number: 68609-97-2

Authority: Health and Safety Authority, Ireland

Date: 21 March 2023

The priority for evaluating the substance has been reconsidered based on:

<input type="checkbox"/>	The initial hazard ground of concern has been verified and considered of low priority

<input type="checkbox"/>	The initial exposure/risk ground of concern has been verified and considered of low priority

<input checked="" type="checkbox"/>	The generation of information under Substance Evaluation is considered of low priority because
	<p><input checked="" type="checkbox"/> Already ongoing or implemented regulatory process(es)</p> <p>ECHA issued compliance check decisions in March 2017 and February 2020, which included requests for an <i>in vivo</i> mammalian alkaline comet assay or transgenic rodent somatic and germ cell gene mutation assay (OECD TG 489 or OECD TG 488), a sub-chronic toxicity study (90-day, OECD TG 408), a pre-natal developmental toxicity study (OECD TG 414) in a first species, a pre-natal developmental toxicity study (OECD TG 414) in a second species and an extended one-generation reproductive toxicity study (OECD TG 443) with oxirane, mono[(C12-14-alkyloxy)methyl] derivs.</p> <p>Since the dossier evaluation process is ongoing and the requested information may clarify the initial concerns identified in the CoRAP justification document, the IE CA withdraws the substance from the CoRAP for now. If the concerns are not addressed by the information provided under dossier evaluation, the substance may be re-introduced to the CoRAP.</p>
	<input type="checkbox"/> Registrants' (voluntary) action addresses concern
	<input type="checkbox"/> Other: